We chose to deliver a polymeric glyco-adjuvantpreviously developed in our laboratory, p(Man-TLR7), which showedstrong efficacy as a vaccinal adjuvant.22 We now pivoted to an immuno-oncology application to adjuvant thetumor cell surface and the neoantigens contained therein and demonstratedthat disulfide binding upon intratumoral injection created an in situ cancer vaccine, inducing strong therapeutic antitumorimmunity as a monotherapy and in combination with checkpoint inhibition. Here, TLR7 is linked to cancer.